COVID-19 vaccination in India

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "COVID-19 vaccination in India" – news · newspapers · books · scholar · JSTOR (October 2023) (Learn how and when to remove this message)

COVID-19 vaccination programme

Per capita fully vaccination map as of 4 April 2023
Date	16 January 2021 (2021-01-16) – present (3 years, 295 days ago)
Location	India
Cause	COVID-19 pandemic in India
Target	Immunisation of Indians against COVID-19
Budget	₹35,000 crore (US$4.2 billion)[1]
Organised by	Government of India Indian Council of Medical Research State governments of India
Participants	1,025,789,302 people with one dose administered of Covaxin or Oxford–AstraZeneca vaccine or Sputnik V 952,033,158 people have been fully vaccinated with both doses of Covaxin or Oxford–AstraZeneca vaccine or Sputnik V or Corbevax 228,593,024 people have been administered Precautionary/Booster doses of Covaxin or Oxford–AstraZeneca vaccine or Sputnik V or Corbevax
Outcome	74% of the Indian population has received one dose. 69% of the Indian population has received both doses
Website	MoHFW
As on 4th March 2023 (07:00AM)

Part of a series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Long COVID Neurological and psychological symptoms Post-exertional malaise Society Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health Migration Military Notable deaths Other health issues Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Politics Diplomacy Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

India began administration of COVID-19 vaccines on 16 January 2021. As of 4 March 2023^[update], India has administered over 2.2 billion doses overall, including first, second and precautionary (booster) doses of the currently approved vaccines.^[2][3] In India, 95% of the eligible population (12+) has received at least one shot, and 88% of the eligible population (12+) is fully vaccinated.^[4][5]

India initially approved the Oxford–AstraZeneca vaccine (manufactured under license by Serum Institute of India under the trade name Covishield) and Covaxin (a vaccine developed locally by Bharat Biotech). They have since been joined by the Sputnik V (manufactured under license by Dr. Reddy's Laboratories, with additional production from Serum Institute of India being started in September^[6][7]), Moderna vaccines, Johnson & Johnson vaccine and ZyCoV-D (a vaccine locally developed by Zydus Cadila)^[a][b] and other vaccine candidates undergoing local clinical trials.

According to a June 2022 study published in The Lancet, COVID-19 vaccination in India prevented an additional 4.2 million deaths from December 8, 2020, to December 8, 2021.^[8][9]

Cite error: There are <ref group=lower-alpha> tags or {{efn}} templates on this page, but the references will not show without a {{reflist|group=lower-alpha}} template or {{notelist}} template (see the help page).